Trial Profile
Efficacy and Safety of Yisaipu, in combination with DMARDs in comparison with low or medium dose of glucocorticoid in patients with moderate to severe Rheumatoid Arthritis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Jul 2017
Price :
$35
*
At a glance
- Drugs Etanercept (Primary) ; Folic acid; Hydroxychloroquine; Methotrexate; Prednisone
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- 05 Jul 2017 New trial record
- 17 Jun 2017 Primary endpoint has been met. (ACR20 response rate at week 24) as per results presented at the 18th Annual Congress of the European League Against Rheumatism
- 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism